New Enhanced OMIDRIAssure® Patient Access Programs

Learn more

Real-world Evidence

Omidria Prevents Ifis1

Patients treated with OMIDRIA had an 84% reduction in observed IFIS symptoms, 79% reduction in iris prolapse, and 90% reduction in severe billowing vs placebo

OMIDRIA inhibits prostaglandin release, thereby reducing inflammation, to maintain iris stability and prevent IFIS.1,2

Single-center, double-masked, prospective, comparative study (N=50)1

In a comparative study, men were randomized 1:1 to OMIDRIA and placebo for cataract surgery

All patients received the standard preoperative topical mydriatic drops and topical benzocaine on the day of surgery.1
All patients had conventional phacoemulsification with video recording using an endocyclophotocoagulation (ECP) probe.1

REFERENCES: 1. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2018;44(9):1103-1108. 2. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Clin Ophthalmol. 2017;11:1039-1043.